DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

DexCom, Inc. DXCM is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported ...

DexCom, Inc. DXCM reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at ...

DexCom is a pioneer in the development of continuous glucose monitoring (CGM) systems, which are used by people managing diabetes. Its innovative devices like the G6 and G7 have set the standard ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices Commodities ...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday. Shares of Capri Holdings Limited CPRI fell sharply in today's pre-market trading following ...

The introduction of sensors like G6 and G7 in international markets also fueled revenue growth. Dexcom anticipates strong growth from its recent product launches and international expansions ...

DexCom, Inc. DXCM is scheduled to release ... DXCM’s continued focus on introducing new sensors like G6 and G7 in international markets and expanding coverage for its sensors is supporting ...

DexCom, Inc. DXCM reported third-quarter 2024 ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over ...